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We report the case history of a 75-year-old woman with Parkinson’s disease who developed severe cognitive problems after deep
brain stimulation (DBS) of the bilateral subthalamic nuclei (STN). After a brief cognitive improvement, the patient gradually
deteriorated until she developed full-blown dementia. We discuss the case with respect to the cognitive eﬀects of STN DBS and the
possible risk factors of dementia after STN DBS surgery.
1.Introduction
Parkinson’s disease (PD) is a degenerative disorder. Clinical
heterogeneity, progressive motor pattern changes, and vari-
ations in the course of the disease are well known [1, 2].
The disease process continues throughout life as there is no
spontaneous or treatment-induced remission. PD subtypes
change with time, and the progression is nonlinear [3]. The
point-prevalence of dementia in PD is close to 30%, and
the incidence rate is 4- to 6-times greater than that of age-
matched controls. The cumulative prevalence of dementia is
at least 75% for PD patients who survive for more than 10
years [4–6].
Although there is no causal treatment for PD, deep
brain stimulation (DBS) of the bilateral subthalamic nuclei
(STN) has been shown to be surgically safe in well-selected
candidates, and subsequent improvements in dopaminergic
drug-sensitive symptoms and reductions in drug doses and
dyskinesias are well documented. However, the procedure
is associated with adverse eﬀects, mainly neurocognitive
and neuropsychiatric, and with side eﬀects created by the
spread of stimulation to surrounding structures, depending
on the precise location of electrodes [7–9]. The morbidity
rates associated with invasive surgery can also be signiﬁcant,
including particularly intracranial bleeding [10, 11].
2. Case History
A 61-year-old woman was diagnosed with PD in 1991. She
hadnofamilyhistoryofPDandshehadnotbeenchronically
treatedforanyothermedicalcondition.Sheworkedasahigh
school teacher until the age of 65.
The ﬁrst symptoms of PD included hyposmia, fatigue,
and tremor and rigidity of the left lower extremity (LLE).
She was ﬁrst put on selegiline. In 1994, she started L-
dopa treatment, which had an excellent eﬀect on the motor
symptoms of PD. In 1995, while the daily dose of L-dopa
was 500mg, the ﬁrst choreodystonic peak-dose dyskinesias
appeared on the LLE. After that, diﬀerent therapies were
prescribed as add-on treatments to the L-dopa, including
dopamine agonists (pergolide, ropinirole), amantadine, and
entacapone. These therapies had transient eﬀects in the
alleviationofboththemotorsymptomsofPDandthemotor
complications.
In 2005, the patient was on a stable antiparkinsonian
medication therapy consisting of ropinirole 5mg tid and L-
dopa plus entacapone in alternating doses of 100mg and
50mg in six 3-hour intervals starting at 7am (altogether,
six doses; total daily L-dopa dose 450mg). At that time,
the patient suﬀered either from generalised tremor and
rigidity accompanied by severe pain of the whole body or2 Parkinson’s Disease
from severe choreodystonic involuntary movements. She
stopped leaving her house and was unable to take full
care of herself. We examined the patient using the Core
AssessmentProgramforSurgicalInterventionalTherapiesin
PD (CAPSIT-PD) [12]. At that time, the patient experienced
no falls, no postural instability, no freezing of gait, and there
was no history of depression, hallucinations, or delusions.
According to a detailed neuropsychological examination in
October 2005, she was declared cognitively normal in all
domains including memory (as measured by the Wechsler
Memory Scale III), executive functions (as assessed by Mattis
Dementia Rating Scale, semantic and phonological verbal
ﬂuency, Tower of London Task, Stroop test), visuospatial
andvisuoconstructiveabilities(asassessedbyRey-Osterrieth
ComplexFigureTest),andspeech[13].TheMattisDementia
Rating Scale score was 144 points, and her IQ as measured
by the Wechsler Adult Intelligence Scale-revised (WAIS-R)
was 129 [13]. No symptoms of behavioural or aﬀective
disorders were present. The brain MRI was normal for age.
Except for PD, the patient was otherwise healthy. She was
very motivated for PD surgery. The L-dopa test was clearly
positive: the Uniﬁed Parkinson’s Rating Scale (UPDRS, [14])
III subscore dropped from 44 to 22 points. Despite her high
age (75 years), she was considered a good candidate for the
procedure.
Bilateral STN electrodes were implanted in December
2005. The stereotactic procedure was performed using the
Leibinger open frame with the Praezis Plus software and the
Talairachdiagram.Weusedthestandardtungstenmicroelec-
trode 291A (Medtronic, Inc., Denmark) with an impedance
of 0.5–1.5MΩ for the intraoperative microrecording and
microstimulation. Once the target coordinates were deter-
mined, a permanent quadripolar DBS electrode (Medtronic,
model 3389 with 0.5mm intercontact distance and 1.5mm
electrode contact width) was implanted. The electrode
position was veriﬁed by the intraoperative use of ﬂuo-
roscopy to compare the position of the trajectories of the
microrecording electrodes with the deﬁnitive trajectory of
the quadripolar macroelectrode [15]. The ﬁnal coordinates
of electrode tips within the STN (x, y,z) were 11.5mm
anteriorly, 3mm posteriorly, 5mm caudally from AC-PC
midpoint. The position of the electrode was conﬁrmed by
postoperative CT scan and X-ray with a stereotactic frame
still mounted.
No complications were observed at the time of surgery;
the patient remained conscious, alert, and cooperative
during all stages of the procedure. Nevertheless, on the day
after the electrode implantation, a transient somnolence,
disorientation in time and space, and retrograde amnesia
occurred. This acute confusion regressed within 4 days. The
electrode cables were internalized, and a neurostimulation
device (Kinetra, Medtronic Inc., Minneapolis, USA) was
implanted. The patient was released from the hospital. She
was rehospitalized one month later in order to start the
stimulation.
In January 2006, a neuropsychological examination was
performed with the stimulation oﬀ while the patient was
on stable dopaminergic medication. It revealed a moderately
intense organic psychosyndrome and a marked dysexecutive
Figure 1: Intersecting pentagons drawing from the Mini-Mental
State Examination reﬂects patient’s disinhibition.
syndrome with a major impact on other cognitive functions
and instrumental activities of daily living. It manifested
symptomatically by decreased psychomotor speed, ﬂexibil-
ity, spontaneity, and concentration, as well as attention
deﬁcits and disinhibition (see Figure 1 for the intersecting
pentagons drawing from the Mini-Mental State Examina-
tion (MMSE, [13])). Mild memory impairment was also
identiﬁed, aﬀecting primarily recent episodic and seman-
tic memory. Visuospatial deﬁcits, dyscalculia, and deﬁcits
in time orientation were also reported, and the patient
became negativistic and dysphoric. Her MMSE score was 14
points and the Montgomery-Asberg Depression Rating Scale
(MADRS) score was 24 [13]. We performed brain MRI and
FLAIR sequences to verify the electrode location and to rule
out possible adverse eﬀects of implantation. The electrodeParkinson’s Disease 3
location was correct; however, mild oedema and bleeding
were found in the anterior limb of the left internal capsule,
spreadingtotheputamenandcaudatehead(seeFigure 2(a)).
The stimulation had been started very slowly. By March,
the stimulation parameters were set at intensities of 2.0 and
2.7V, for the left and right sides, respectively, with a 130Hz
frequency, and 90µsec pulse width. The stimulated contacts
were 2 and 6, respectively. The patient’s motor symptoms
of PD and motor complications improved signiﬁcantly.
The Uniﬁed Parkinson’s Rating Scale (UPDRS, [15]) III
subscore in the oﬀ medication state improved from 44 to
21 points. The UPDRS IV subscore decreased from 4 to
0 points. Ropinirole was decreased to 7.5mg/day, L-dopa
was decreased to 300mg/day (administered in 6 doses),




Mild cognitive impairment, with the predominant in-
volvement of the frontal lobes, was reported during neu-
ropsychological testing in June 2006 (see Table 1), aﬀect-
ing verbal ﬂuency, motor sequential tasks, and strategic
planning. Mild dyscalculia, recent memory, and visuospatial
memory impairments were also identiﬁed, but the global
cognitive performance was within the normal range; the
MMSE score was 27. At that time, the previously described
pathologyobservedonthebrainMRIhadpartiallyregressed.
However, the MRI results in May 2006 still demonstrated
hyperintensity changes along the left electrode trajectory in
the area of the genu of internal capsule, and the medial
edge of the lentiform nucleus reaching to the left thalamus
(see Figure 2(b)). On the whole, the clinical status of our
patientimprovedfromthemotor,behavioural,andcognitive
points of view. In June 2006, the stimulation intensity was
3.3 and 3.7V, for the left and right sides, respectively,
while the antiparkinsonian medication remained stable
with no changes. We tried to introduce acetylcholinesterase
inhibitors (rivastigmine, donepezil) but the patient did not
tolerate any of the drugs because of nausea and vomit-
ing.
During the summer of 2006, the patient’s medical condi-
tion again started to gradually deteriorate, with episodes of
freezing of gait and postural instability, visual hallucinations,
and delusions. The behavioural disturbances were worse in
the morning. The patient experienced no tremor. Sometimes
she had very mild dyskinesias on the left side, but no
motor ﬂuctuations were present. She left the house and
got lost repeatedly, and she became partially dependent
on the caregiver (her husband). Quetiapine was started at
that time with a dose titration up to 75mg per day; this
was later exchanged for clozapine in low doses (50mg per
day). All other medications except L-dopa (550mg/day) and
citalopram (20mg/day) were withdrawn. Cognitive testing
in March 2007 conﬁrmed the cognitive decline, with a
Mattis Dementia Rating Scale score of 116 points and
an IQ score measured at 90. In addition to dysexecutive
syndrome,memoryfunctions,andpraxis,visuoconstructive,
visuospatial, and other cognitive functions were impaired,
including writing and picture drawing.
In 2008, full-blown dementia was reported, which pro-
gressed over time. Memantin (20mg per day) was intro-
duced, but no visible eﬀect on slowing the dementia course
wasdetected.InDecember2008,amarkedoverallbrainatro-
phy was depicted in brain MRI, including both hippocampi.
Whitematterhyperintensitiesalongtheelectrodetrajectories
(possible gliosis) were also visible (see Figure 2(c)). In 2009,
the MMSE score was 19, and according to the 7-min subtests
[13], orientation in time score was 74, enhanced cued
memory score was 8, the clock test score was 1, and semantic
verbal ﬂuency was 5. In February 2010, the stimulation
battery was changed, with the last stimulation parameters
being as follows: amplitude 3.6V and 3.8V for the left and
right sides, respectively, stimulation frequency 130Hz, pulse
width 90µsec. The MMSE was 14. The patient suﬀered
from hallucinations, delusions, and postural instability with
occasional falls. She had severe aphasia and dysarthria with
telegraphic slurred speech and moderately severe motor
and ideomotor apraxia. She became incontinent, and fully




Our patient suﬀered from intracranial bleeding as a con-
sequence of the STN electrode implantation. Intracerebral
hemorrhages (ICHs) have been known to occur as possible
adverse eﬀects of DBS surgery in 1 to 4% of cases, according
to literature reports of case studies, large studies, and
meta-analyses [10, 11, 16–21]. These manifest as transient
neurological symptoms, some with complete recovery and
others with long-term deﬁcits. In our patient, the speciﬁc
location of the ICH including the left striatum and thus
involving the frontostriatal circuitry could have explained
an abrupt cognitive deterioration and marked dysexecutive
syndrome in particular [22–24]. The possible risk factors of
ICH include particularly arterial hypertension. The impact
of the use of microelectrode recordings and of an increased
number of microelectrode trajectories have been rather
controversial [17–19, 25]. Older age and male sex have also
been associated with hemorrhage, according to some studies
[19, 26]. Our patient had normal blood pressure; however,
her advanced age might have played a role.
Interestingly, our patient partially recovered, but approx-
imately 8 months after the surgery she again started to
deteriorate cognitively until full-blown dementia developed
within 2.5 years after the DBS surgery. Although the vast
literature on cognitive short-term as well as long-term
outcomes after bilateral DBS surgery of the STN varies and
remains rather controversial, mild to moderate decreases
in verbal ﬂuency have been reported as the most common
after-eﬀects of the procedure (e.g., [7–9, 27–32]). The exact
mechanisms of possible cognitive eﬀects of STN DBS are not
known. The precise location of the active electrode contact
and the spatial extent of the eﬀects of stimulation as well as
the frequency, voltage, and amplitude of STN stimulation, or
patientvariablessuchasdegreeofdopaminergicdenervation









Figure 2: (a) Fluid-attenuated inversion recovery magnetic resonance imaging (FLAIR MRI) in January 2006 shows mild edema and
bleeding in the anterior limb of the left internal capsule and left striatum. (b) FLAIR MRI in May 2006 still depicts signal changes along
the left electrode trajectory in the internal capsule, medial edge of the lentiform nucleus reaching to the left thalamus. (c) FLAIR MRI in
December 2008 demonstrates marked brain atrophy and white matter hyperintensities along the electrode trajectories.
Conversely, development of dementia has been generally
related to the PD progression itself [30–32]. According to a
Sydneystudy,48%ofPDpatientshaddementiaafter15years
of the disease progression and 83% after 20 years of having
PD [5, 35]. Other studies have reported the cumulative
prevalence of dementia to be least 75% among PD patients
w h os u r v i v ef o rm o r et h a n1 0y e a r s[ 36]. The most estab-
lished risk factors for dementia in PD (PDD) are higher age,
severity of motor symptoms, in particular postural and gait
disturbances, cognitive impairment at baseline, and visual
hallucinations. Other risk factors, such as lower education
and socioeconomic status, later disease onset, longer disease
duration, positive family history, depression, and REM sleep
behavioural disorder have also been reported (e.g., [4–6, 35,
36]). Of all the above-mentioned factors, old age (75 years
at the time of DBS and 78 years at the time of dementia
diagnosis) and long disease duration (17 years at the time
of dementia diagnosis) were the most marked risk factors to
take into account in our patient.
The time from onset of PD to dementia varies con-
siderably [36, 37]. There is a growing body of evidence
derived from clinicopathological studies to suggest that there
are diﬀerent PDD subtypes depending on the age at PD
onset and the disease duration. A less malignant type with a
long time to dementia onset is characterized by Lewy body
distributions consistent with the Braak staging of diseaseParkinson’s Disease 5
Table 1: Neuropsychological test battery results.
Psychological test Examination date
10/2005 1/2006∗ 3/2006∗∗ 6/2006 11/2006 3/2007 7/2008
WAIS-R (IQ) 129 14 MMSE only 102 27 MMSE only 97 90
Mattis DRS (raw/maximum score)
Total score 144/144 116/144 84/144
Attention 37/37 35/37 31/37
Initiation 37/37 29/37 14/37
Construction 6/6 5/6 2/6
Conceptualization 39/39 30/39 26/39
Memory 25/25 17/25 11/25
WORD-LIST WMS III (raw/scaled score)
1st trial 5/12 3/7 2/6 2/6
Immediate recall 29/11 22/7 13/4 15/4
Delayed recall 4/11 4/11 1/8 0/6
Recognition 22/10 23/11 18/7 15/4
Verbal ﬂuency tests (raw score)
Category (animal) 20 1 14 7 4 6
l e t t e r( N ,K ,P ) 4 5 1 9 6 1 0 7 5
Rey-Osterrieth CFT (raw/T score)
Copy (raw) 36 33 32.5 28 4.5
Immediate recall 21/67 10/43 15/57 12.5/52 1.5/25
Delayed recall 18.5/62 13/49 13.5/54 9/43 failed
Recognition 29/49 20/49 21/56 20/50 14/20
Stroop test (raw/T score)
Word 98/45 97/45 103/47 93/43 56/24
Color 73/45 61/37 65/40 34/20 31/20
Word/color 49/54 33/38 39/44 25/30 failed
Interference (T score) 57 50 49 55 —
Tower of London (raw/maximum score) 33/36 8/36 failed
MADRS 4 24 9 5 3 8
∗1/2006: very poor compliance—only screening; ∗∗3/2006: still poor compliance, but much better than during the previous examination in 1/2006; WAIS-
R: Wechsler Adult Intelligence Scale—Revised; Mattis DRS: Mattis Dementia Rating Scale; WMS III: Wechsler Memory Scale III; Rey-Osterrieth CFT: Rey-
Osterrieth Complex Figure Test; MADRS: Montgomery-Asberg Depression Rating Scale.
[37, 38], while a more malignant course occurs in people
with older age at PD onset and shorter survival shows more
brain atrophy and both higher Lewy body and Alzheimer’s
disease plaque pathology [37]. In our case, the major brain
atrophy also seen in the hippocampus, that is, a ﬁnding
typical of Alzheimer’s disease, could have been related
to possible coincidence of PD dementia and Alzheimer’s
pathology and could at least in part explain the malignant
course. Unfortunately, the brain biopsy was not performed
since the family did not approve it.
Another interesting issue that has to be taken into
consideration relates to possible gliosis along the electrode
trajectories. It has been shown by others [39] that DBS
electrodes may cause a giant cell reaction or gliosis around
them when implanted in the brains of patients with PD. This
reaction is present from 3 months to at least 31 months
onwards after implantation, and may possibly represent a
response to the polyurethane component of the electrodes’
surface coat. The accumulation of inﬂammatory tissue
occurs predominantly around the electrode sheath rather
than tip, and it is conceivable that on the whole it plays only
a small role in maintaining beneﬁt or causing side eﬀects of
DBS [39].
Finally, we indeed cannot exclude a possibility that the
ICH as an adverse event of the STN implantation might not
only have caused an acute cognitive and behavioural impair-
ment after the procedure but might also have accelerated
the development of dementia in our patient, probably as a
resultof collapsed brain reserve and disturbed compensatory
mechanisms caused by the electrode implantation and IHC.
Age was probably the major contributor and risk factor for
the intracranial bleeding, postoperative confusion, and later
dementia development [26, 40, 41].
Despite many unresolved questions, this has taught us
not to include PD patients above 70 years of age for the DBS
surgery.Inaddition,thelengthofPDdurationshouldalsobe
takenintoconsideration,andthequestionremainsastowhat
the best time for considering DBS in PD would be. Further6 Parkinson’s Disease
research should focus on potential biological markers such
as speciﬁc brain imaging techniques and cerebrospinal ﬂuid
examination that would better predict the disease prognosis
and that might help to better select good candidates for DBS
surgery in PD patients.
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